RxDoctor Payments Data

Saqib Gowani, MD

Interventional Cardiology · Kissimmee, FLNPI 1598067498

Payments from drug & device makers

$71,813in general payments, 2019–2025

Across 330 payments — averaging $217.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$33K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26K
  • Medtronic$4K
  • Abiomed$2K
  • Abbott$1K
  • Medical Device Business Services, Inc.$1K
  • plus $5K from 25 others

What the payments were for

  • Speaking & faculty fees$43,10060%
  • Travel & lodging$10,85615%
  • Food & beverage$17,68225%
  • Education$1750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,813 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$272,210
Medicare patients
1,303
Services billed
3,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$139,738
EntrestoSacubitril/Valsartan25$40,230
BrilintaTicagrelor45$37,965
JardianceEmpagliflozin20$26,002
FarxigaDapagliflozin Propanediol12$15,399
XareltoRivaroxaban13$14,543
Ranolazine ErRanolazine20$2,921
Torsemide128$2,267
Metoprolol Succinate111$1,574
Atorvastatin Calcium145$1,324
ClopidogrelClopidogrel Bisulfate95$1,143
Hydralazine Hcl40$1,029
Carvedilol72$885
Losartan Potassium69$612
Amlodipine Besylate83$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$139,738119 claims
AstraZenecaBrilinta, Farxiga$75$53,36457 claims
NovartisEntresto$170$40,23025 claims
Boehringer IngelheimJardiance$24$26,00220 claims
Johnson & JohnsonXarelto$34$14,54313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →